Jing-Yi Chung

This paper develops a non-viral BCMA CAR-T therapy using CRISPR and 1XX signaling, showing improved safety, potency, and persistence in multiple myeloma.

This paper develops a genome engineering workflow for primary human NK cells using CRISPR/Cas9 and AAV6 to integrate and disrupt genes, enhancing anti-tumor function through targeted CAR expression.

The paper develops a non-viral method using hybrid ssDNA repair templates to improve genome engineering in primary human cells, achieving high knock-in efficiency and cell yields for disease modeling and cell therapy.